

Research Article

Mechanism of multi-resistant bacterial pathogenesis: MDR genes are not so deadly unless plasmid-mediated toxin, virulence and regulatory genes are activated

Kousik Poria, Shampa Bhatta, Sanatan Das, Madhumita Dey, Chandan Halder, Sankalita Datta and Asit Kumar Chakraborty*

Department of Biotechnology and Biochemistry, Oriental Institute of Science and Technology, Vidyasagar University, West Bengal, Midnapore 721102, India

Received: 30 January, 2020

Accepted: 02 April, 2020

Published: 04 April, 2020

*Corresponding author: Asit Kumar Chakraborty, Department of Biotechnology and Biochemistry, Oriental Institute of Science and Technology, Vidyasagar University, West Bengal, Midnapore 721102, Tel: +917679154141; India, E-mail: chakraakc@gmail.com

Keywords: Toxin genes; Mdr genes; Superbug horror; Gut microbiota symbiosis; Mdr conjugative plasmid; Antibiotic contamination; Transcriptional activators

<https://www.peertechz.com>



Summary

Mdr genes in association with many drug efflux and metal efflux genes are creating pathogenesis due to antibiotic void. However, most dangerous step occurred when R-plasmids and integrons (~2-9kb) were combined with F'-conjugative plasmid (62.5kb) creating large MDR conjugative plasmids that easily donated 6-15 *mdr* genes to gut microbiota as well as environmental bacteria. Notably, $2-4 \times 10^{12}$ human gut microbiota are very valuable in our body for vitamins synthesis and coenzymes perform >30,000 enzymatic reactions of human and animal metabolosome. It seems *mdr* gene creation is becoming more easy day by day as plasmids have acquired many gene creation genes like recombinases, DNA polymerases, DNA topoisomerases, integrases and transposases. In truth, antibiotics pressure was so instrumental that 25-40% bacteria of Ganga River and Bay of Bengal water were ampicillin and tetracycline resistant and more than 20 class of β -lactamases and drug transporters were generated in MDR plasmids with millions of mutated isomers increasing drugs MIC. When isolated superbugs were injected into male Wister rats, no detectable toxicity was observed up to 3-6 months follow up. We propose that *mdr* genes are not so injurious unless toxins and virulence genes with signalling and transcriptional regulators are activated in plasmids. Likely, *mdr* genes are protected by a tight symbiosis involving bio-film formation in the gut for vitamin synthesis. We also found a gradual increase of larger plasmids in the GenBank database with multiple *mdr* genes, drug efflux genes, regulatory genes, vitamin synthesizing genes and metal resistant genes as well as abundant (20-40) transposons and IS-elements. WHO, UNDP and CDC have suggested to develop alternate to antibiotics like phage therapy, gene therapy and nanotechnology based toxic drug delivery. We are actively using heterogeneous phyto-antibiotics from *Suregada multiflora* (root), *Cassia fistula* (bark) and *Trapa bispinosa* (fruit peel) targeting superbug central dogma machinery with success.

Introduction

Many toxins like Stx1, RTX, ByB, Enterotoxin, Neurotoxin, Hemolysin, HipA and virulence proteins have been involved in acute bacterial pathogenesis [1,2]. However, recent trends to blame *mdr* genes (*amp*, *bla*, *cat*, *aac*, *dhfr*, *str*, *aph*, *aad*, *mcr*) and drug efflux genes (*tet*, *mac*, *acr*, *mex*, *mtr*) in bacterial pathogenesis have roared due to drug void [3-5]. We blame many toxins and regulatory genes as acute problem in recent bacterial pathogenesis while tremendous amount of transposons

and insertion sequences may be serious concern for the alteration and transmission of genes. Now MDR bacteria were detected in river, sea and air as well as in hospital surgical and household matters, claiming 2000,000 deaths per year likely among the neonatal and elderly with weak immune system where 10-20 potent antibiotic therapy were failed [6-9]. So, we re-evaluated the status of *mdr* genes in plasmids and genome islands in association of toxins and regulatory genes.

Before 1600s we do not know that microorganisms (virus,

bacteria, fungus and parasites) cause diseases and we blame ghosts and demons. After the discovery of microscope by Anton Van Leeuwenhoek (1670s) and further pioneering works by Edward Jenner (1790s), Lewis Pasteur (1860s) and David Koch (1880s) proved that bacteria were the culprit of many diseases like TB, Cholera, Gonorrhoea and Typhoid [10]. Eventually the unicellular unseen bacteria were in centre stage of biochemical and molecular biological studies to decipher the central dogma processes like replication, transcription and translation to control diseases by antibiotics. Such study is important as basic chemical reactions of formation of DNA, RNA, protein, sugar, and fat are same among the all life forms. Our body is made of 30-40 trillions cells which are also microscopic (5-100 μ m). Thus, understanding the molecular assembly of molecular biological processes is vital to design drugs against deadly pathogens [11]. Biomolecules are nanometer and could be analyzed by assembly (10^7 - 10^{15} molecules) using suitable sensitive methods like UV detection of Ethidium bromide stained DNA/RNA, Ninhydrin colour reaction of amino acids, and absorption spectra analysis technologies like MASS, NMR, FT-IR and Raman Spectroscopy [12]. Main point is research is now becoming costly and needs sophisticated machines and talented scientists mostly found in developed nations. Indian peoples are in serious financial crisis as the cost of imported new drugs are very high and almost out of reach for poor patients [13]. Thus we believe in heterogeneous phyto-antibiotics developed by ancient Hindu Civilization.

Discovery of antibiotics that kill bacteria to cure many diseases

Notably, antibiotics are in centre stage of discoveries since the discovery of penicillin drug by Nobel Laureate Alexander

Flaming from slime mold *Penicillium notatum* in 1928 targeting peptidoglycan cell wall biosynthesis of most Gram(+) and few Gram(-) bacteria [14]. Since then, hundreds derivatives were made alone for penicillins (ampicillin, cefotaxime and imipenem etc) for better drug usually called penicillinases resistant drugs (for chemical structure Figure 1). Dr. Selman Waksman discovered over twenty antibiotics that led to Nobel Prize in Physiology or Medicine in 1952 [15]. Most importantly, streptomycin was alone greatly reduced the TB in 1950s [16]. However, such dream could not last long as more potent penicillinases called, oxacillinases (blaOXA), cefotaximases (blaCTX-M), carbapenemases (blaKPC) were appeared in bacterial plasmids between 1940-1990 increasing drug resistance and antibiotic failure [17-20].

MDR proteins and drug transporters prevent the action of antibiotics and save gut bacteria

Bacteria simply made 100 different enzymes like β -lactamases, acetyl-transferases, phospho-transferases that all could destroy antibiotics by different modes of action [21]. β -lactamases have been grouped into four major classes (A-D) based on sequence homology but diverged more profoundly into 20 sub-classes as described recently [22]. Million of *mdr* genes have been sequenced that includes mostly *bla* genes (*TEM*, *SHV*, *KPC*, *CTX-M-1/2/9*, *OXA2/23/48*, *VIM*, *CMY*, *GIM*, *SPM* etc), drug modifying genes like *catB3* (chloramphenicol acetyl transferase), *aadA1-10* (aminoglycoside adenylyl transferase), *aacA1-42* (drug acetyl transferase), *aph-I-IX* (aminoglycoside phosphotransferase), as well as *sul1/2*, *arr3*, *dhfr*, *mcr-1* and *vanA* genes [23,24]. Diverse range of drug transporter genes like *acrAB*, *macA/B*, *mexCD/EF*, *bcr*, *bmr*, *teta/C*, *norA* and *mtrCDE* are activated in plasmids and chromosome and had arose due




Figure 1: Structures of complex antibiotics those would be now inactivated by multidrug-resistant enzymes of bacteria. Those and other antibiotics killed gut microbiota hampering vitamins and other biomolecules biosynthesis.



to mutation and recombination among 200 ABC transporters that would otherwise regulate the entry and exit of organic and macromolecules into bacterial cells [25]. So, such bacteria in our body stay alive and divide most to cause sepsis and trauma and condition will not be going to improve by taking prescription drugs because no achievable concentration of the drug would be happen in bacterial cytoplasm to stop protein synthesis, RNA synthesis and cell wall synthesis [12]. In truth, drug industry has so far busy to discover new antibiotic derivatives to overcome the actions of *mdr* genes but now very much reluctant to invest on new antibiotic discovery due to quick drug inactivation creating *mdr* enzymes [6,7].

MDR conjugative plasmids ubiquitously donate *mdr* genes into all gut and environmental bacteria

Study confirmed that all early plasmids carried 2-3 *mdr* genes as in pSC101 or pMB that were used to make semi-synthetic plasmid pBR322 that was sequenced in 1965 to discover the *mdr* genes *amp* and *tet* [18]. It was found that due to plasmid incompatibility (Inc plasmids), one bacterium could not carry multiple different plasmids. However, intake of continuous multiple doses different antibiotics have prevented vitamin synthesis in the gut. So save your soul has worked and bacteria have used its conjugative plasmid (F') as carrier of *mdr* genes to transmit genes into new bacteria by a process known as conjugation. More than twenty *Tra* genes in conjugative plasmids code for proteins that can form sex pili connecting other bacteria to send DNA into it [26-28]. Bacteria combined R-plasmid (3-9kb) with F'-plasmid (62.5kb) and such plasmid was known today as conjugative MDR plasmid which could be large as 50-500kb [29]. Bacteria got very advantage for life as such plasmids are very stable in bacteria during cell division and also can carry multiple *mdr* genes and can donate the *mdr* genes to non-MDR bacteria to save from deleterious effects of antibiotics and toxic chemicals [30,31]. In 1928 to 2018, we did lots of chemistry and recombinant DNA technology and gene manipulation but at the end we got PAN drug resistant bacteria! Phage therapy, gene therapy, phyto-antibiotics and nanotechnology are new technologies to avert the drug void. We believe heterogeneous phyto-antibiotics which will rule the future Earth to save human again from superbugs as depicted in ancient Hindu Civilization history like Sanskrit books Charaka Samhita, Susruta Samhita and Atharva Veda [12].

Toxins and regulatory transcription factors are chromosomal origin

Toxin genes are those that have profound mechanisms to cause severe toxicity in host to create acute pathogenesis. Cholera toxin was discovered in 1959 and contained one subunit A (28KB) and five subunits of B (11KB). While subunit B help to bind membrane GM1 gangliosides, subunit A activates (100x) cytosolic adenylyl cyclase by ADP-ribosylation of *G α s* (also prevents GDP hydrolysis) to generate cAMP which in turn activates CFTR chloride efflux protein through PKA kinases to exclude Cl⁻ as well as other ions and water to cause watery diarrhoea (2liter/hr) and life threatening dehydration condition [32,33].

Salmonella typhus toxin has three subunits where five PltB subunits make a pyramid-shaped molecule with one molecule each of PltA subunit and CdtB subunit. CdtB has DNase activity while PltA and PltB have ATP ribosylation activity similar to pertussis toxins [34]. Typhoid toxin binds to the podocalyxin-like protein or CD34 sialomucin protein with sialylated glycan (terminal Neu5Gc) in epithelial and endothelial cells or CD45-like protein in hematopoietic cells. It has been postulated that Rab32 GTPase is essential for toxin docking into different human cells to generate immunogenicity and fever. But critically *Salmonella* toxin can stop cell division at G2/M phase likely due to activation of CDK kinase through P53 TF that induces cyclin inhibitor [35,36]. Bacteria can alleviate toxin toxicity by toxin-antitoxin homeostasis [37-40].

We have analyzed the recent trend of plasmid characteristics in MDR bacteria of Ganga River of Kolkata and propose a model where MDR bacteria are quite safe and such *mdr* proteins actually protect gut bacteria for vitamin synthesis saving human race. To pinpoint many MDR bacteria were tested in male Wister rats to show minimum effects for long time. A database analysis confirmed the localization of toxin genes, *mdr* genes, regulatory genes in large plasmids of diverse species of Enterobacteriaceae.

Materials & methods

Water collection and drug sensitivity assay

Water from Ganga River was collected on Monday morning from Babu Ghat (Kolkata-700001). About 100 μ l of water was spread onto 1.5% Luria Bartoni-agar plate containing different antibiotics at 5-50 μ g/ml. MDR bacteria were selected in agar-plate containing ampicillin+ streptomycin+ chloramphenicol+ tetracycline or ciprofloxacin at 50, 50, 34, 20 μ g/ml respectively. As imipenem and meropenem resistant bacteria were present low (0.08-0.2 cfu/ml water) and a modified method was followed. 2 ml 5x LB media was added into 10 ml Ganga River water or Digha sea water and drug was added at f.c 2-10 μ g/ml and was incubated 24 hrs to get carbapenem resistant bacterial population [13]. Antibiotics were purchased from HiMedia and stored at 20-50mg/ml at -20°C. Antibiotic papers were also purchased from HiMedia according to CLSI-2017 standard. Antibiotic papers are: Amp-25 (ampicillin), Met-10 μ g (methicillin), CAZ-30 μ g (ceftazidime), AT-50 (aztreonam), T-10 (tetracycline), COT-25 μ g (cotrimoxazole), LOM-15 μ g (lomofloxacin), VA-10 μ g (vancomycin), AK-10 μ g (Amakacin), LZ-10 μ g (linezolid), TGC-15 μ g (tigecycline) and IMP-10 μ g (imipenem).

Isolation of genomic DNA and plasmid DNA

Genomic DNA was isolated by Proteinase-K-SDS method following extraction with phenol-CHCl₃-isoamyl alcohol (25:24:1) and ethanol precipitation [9]. 1.5 ml over night culture was spun at 5000rpm and the bacterial pellet was dissolved in 50 μ l TE buffer (10mM TrisHCl PH 8.0 + 1mM EDTA) and 25 μ l 10% SDS and 5 μ l of 20mg/ml proteinase-K were added, incubated for 2-4 hrs and extracted with 25 μ l 5M sodium chloride and 100 μ l CHCl₃: isoamyl alcohol (25:1). Then centrifuged at 10000



rpm for 10 min. and the DNA pellet was dissolved in 50µl TE buffer, treated 1µl RNase A and extracted with phenol-CHCl₃-isomyl alcohol (25:24:1) and was precipitated with 1/9 vol. of 3M sodium acetate P^H 5.2 and 2 volumes of ethanol. The plasmid DNA was isolated from overnight culture using Alkaline-Lysis Method [41]. Simply, to 1.5ml bacterial pellet 100 solution-I was added and mixed well. Then 200µl of cold Solution-II added to make transparent solution and then 150µl cold of Solution-III was added and mixed well and centrifuged at 10000rpm for 10min. To clear solution then added 1 ml 99% ethanol and centrifuged at 10000 rpm for 10 min at 4°C. Plasmid DNAs from four such preparation were combined and the RNA were removed by RNase-A treatment as above and finally plasmid DNA was dissolved in 50µl TE buffer and was stored at -20°C. 0.8% agarose gel electrophoresis in 1x TAE buffer at 50V for 4 hrs was performed to see the plasmid DNAs after staining in 0.5µg/ml ethidium bromide and UV illumination [42].

PCR and DNA sequencing

16S rRNA gene colour Sanger's di-deoxy sequencing was performed by SciGenom Limited, Kerala, India) [43]. PCR amplification was performed using 1 unit Taq DNA polymerase, 20ng DNA template, 0.25mM dXTPs, 1.5mM MgCl₂, for 35 cycles at 95°C/30" (denaturation)-52°C/50" (annealing)-72°C/1.5' (synthesis). The product was resolved on a 1% agarose gel in 1X TAE buffer at 50V for 4 hrs and visualized under UV light and photograph was taken [12]. MDR genes fragments were purified and were sequenced by di-deoxy method at SciGenom Labs Pvt Ltd, Kerala, India. The primers for 16S rRNA amplification and *mdr* genes are given below. NCBI BLAST analysis was performed for bacterial specific gene analysis (www.ncbi.nlm.nih.gov/blast) and data was submitted to GenBank.

Primers used in this study.			
Name	Sequence of the primers	Tm	size
P27F	5'-AGA GTT TGA TCC GAA CGC T-3'	62°C	1.4kb
P1392R	5'-TAC GGC TAC CTT GTT ACG ACT TCA-3'	65°C	
<i>cmrF</i>	5'-TTC GTT AGT CTG CCG TTG CT-3'	56°C	323bp
<i>cmrR</i>	5'-ATC GCT GGC AAA CAG GGT TA-3'	57°C	
<i>tem-sF1U</i>	5'-ATGATGAGCACYTTTAAAGT-3' Y=C/T	56°C	312bp
<i>tem-sR1U</i>	5'-TCATTGAGYTCGGKTTCCCA-3' Y=C/T; K=G/T	58°C	
<i>tetF</i>	5'-CTT CGC TAC TTG GAG CCA CT-3'	57°C	910bp
<i>tetR</i>	5'-GCA GAC AAG GTA TAG GGC GG-3'	57°C	
<i>acrAB-F</i>	5'-ATG CTC TCA GGC AGC TTA GCC-3'	59°C	.1kb
<i>acrAB-R</i>	5'-TGT CAC CAG CCA CTT ATC GCC-3'	59°C	
<i>ctxF1U</i>	5'-AACACMGCMGATAATTCACA-3' M=A/C	59°C	586bp
<i>ctxR1U</i>	5'-CCGCRATATCRTTGGTGGTG-3' R=A/G	61°C	

Preparation of organic phyto-extract (MDR-Cure)

The bark of *Suregada multiflora* (Ban-Naranga), *Cassia fistula* (Bandor-Lathi) were collected on July- November 2017-2019 from medium sized tree at Midnapore district of West Bengal. Each 10gms dried and grinded plant and spice parts (*Suregada multiflora*, *Cassia fistula*, *Syzygium aromaticum*, *Cinnamomum zeylanicum*) was suspended in 40 ml ethanol and overnight extracts were mixed and concentrated 5 times (MDR-Cure) and 50µl used for Kirby-Bauer agar hole assay. Thin Layer Chromatography (TLC) was performed using methanol, water and acetic acid (50:40:10) as mobile phase for 1 hr. Organic

molecules were seen and recovered by UV shadowing and was eluted in ethanol from silica-gel. TLC-purified chemicals were purified by HPLC High Performance Liquid Chromatography). Mass spectrometry (Mass), NMR (Nuclear Magnetic Resonance spectrometry) and FTIR (Fourier Transformed Infra Red spectrometry) are then performed to characterize functional groups of active principles in MDR-Cure extract [12].

Animal experiment

Male Wister rats (30-35g) were feed with granules made with (flour 100g + suzi 100g+ mustard oil 100ml+ sugar 100g+one multivitamin tablet). About ~5X10⁶ MDR bacterial suspension (0.5ml) was injected subcutaneously to male rats. Then the rats were challenged with 0.5 ml MDR-Cure extract or 0.5 ml cefotaxime (50mg/ml). After two weeks, blood was collected by tail puncture and bacterial colony forming units were determined on LB-agar plate. The blood smear was drawn on slide and stained with Leishman stain and observed under microscope. Importantly MDR-Cure eliminated 80-90% *mdr*-bacteria but 3rd generation cephalosporin could not do that. The infected rats were kept for 3-6 months if *Escherichia coli* KT-1_ *mdr* and *Pseudomonas aeruginosa* DB-2_ *mdr* could able to kill the rats [30]. But even after 3 months rats were very active demonstrating *mdr* bacteria were not life threatening unless toxin and virulence genes were activating. The animal experiment was approved by Animal Ethics Committee of OIST.

Result and discussion

R-plasmids and MDR conjugative plasmids with multiple *mdr* genes

Mdr genes were identified in 1965 after the discovery of DNA sequencing and Recombinant DNA Technology. *Amp*, *tet*, *cat* and *dhfr* genes were identified early between 1940-1965. So small R-plasmids and integrons and IS-elements (transposons) are sequenced in 1965 and onwards as cloning of DNA were introduced and di-deoxy sequencing was available. We see the structure of recombinant pBR322 plasmid where *amp* and *tet* genes were located (Figure 2C). In truth pBR322 was a DNA recombinant product of three plasmids preparation from penicillin and tetracycline resistant bacteria, derived by cutting with restriction endonucleases like *EcoR1* and *HindII*, and then joining with DNA ligase enzyme. Such DNA breakage and reunion naturally occurred where 62kb conjugative plasmid (Figure 2B) combined with R-plasmid (Figure 2C) to form super conjugative plasmid (Figure 2A). The primary amino acid sequences of *amp* and *tet* *mdr* genes are given in Figure 3A (AMP beta-lactamase) and Figure 3B (tetracycline efflux protein). We introduced such data to make it clear that such genes were mutated so drastically that hundred of isomers were generated with almost no sequence homology to the parent *amp* and *tet* genes. *Amp* gene was renamed as *bla* gene. There were at least 20 distinct classes of *bla* genes like *blaTEM*, *blaCTX-M*, *blaOXA*, *blaKPC*, and *blaNDM* etc and each had few hundred isomers so far sequenced from clinical isolates of multidrug-resistant bacteria. Similarly, *tet* gene has *tetC*, *tetO*, *tetM*, *tetS* etc isomers and all inactivate tetracycline by drug efflux or drug binding. Notably, huge antibiotic prescription




Figure 2: Generation of MDR-Conjugative plasmid (A). MDR-conjugative plasmids are generated by combination of 62.5kb F-plasmid (B) and 3-15kb R-plasmid (A). MDR genes are *bla*, *amp*, *aac*, *aph*, *str*, *mcr*, *cat*; *sul*, and *arr*; Drug efflux genes are *tet*, *acrAB*, *envCD*, *mexAB/CD*, *macA/B*, *mtrCDE*; metal resistant genes are *PcoA*, *telC*, *arsABC*, *merA* and *merC*; and 20 *Tra* genes code conjugative proteins that form sex pili. IS is mobile element or transposon and large MDR plasmid may contain 10-60 such genes facilitating new gene creation and over expression of *mdr* genes. *un* is unknown genes whose functions remains to be determined and likely involved in gut microbiota protection.

cell wall peptidoglycan biosynthesis is a best target for drug development against bacteria as human has no cell wall, but we fail and bacteria won so far. The generation of diverse types of Beta-lactamases due to action of penicillin, cephalosporin and carbapenem drugs was presented in Figure 5.

K. pneumoniae 151kb plasmid (pKP048) (accession no. FJ628167) contains *mdr* genes like macrolide ABC transporter, floquinolone resistant gene (*qnrB4*), mercury resistant gene (*MerE*), sulphonamide resistant protein (*sul1*) and *aph* gene for aminoglycoside phosphotransferases. *BlaKPC1* gene was located in *K. pneumoniae* plasmids (accession nos. NC_022078, NC_014312, JX283456 and KF954759) and *blaNDM1* gene was also located in many large conjugative plasmids (CP009116, JN420336 and AP012055) [Dotson et al., 2016]. Plasmid pKOX_R1 contains metal resistant genes and many ABC, MFS, AAA drug transporters as well as common *mdr* genes like *cat*, *sul1*, *aac3'-IId*, *FosA3*, *ANT*, *aph* and NDM-1, CTX-M-3 and SHV-12 β -lactamases. Most importantly such plasmids has less *Tra* genes but 16 types of inserted IS-elements and transposons.

Detection of toxin genes in plasmid indicates multi-resistance will create more calamities

Escherichia coli medium sized plasmid (P2; accession no.

```
Amp gene encoded Beta-lactamase (pBR322)
001 msighfrval ipffaaafclp vfahtpetlvk vkdaedqlga rvgyiieldln sgkilesfrp
061 eerfpmmstf kvllcogavls rvdaggeqlg rrihysqndi veyspvtekh ltdgmtvrel
121 csaaitmsdn taanllltti gpgkeltafll hnmgdhvtrll drwepelnea ipnderdttm
181 paamatlrk lltgelltla srqglidwme adkvagpllr salpagwfa dksagagergs
241 rgiaaalpdp gkpsrivviy ttgsqatmde rnrqiaeiga sli khw

TetC gene encoded tetracycline efflux protein (pBR322)
001 mksnnalivi lgtvtldavq iglvmpvlpq llrdvhsds iaahygvlla lyalmqflca
061 pvlgaesdrf grpvlasl lgatidyaim attpvlwily agrivagigtg atgavagayi
121 aditdgedra rhfglmsacf gvgmavpva glllgaislh apflaaavl nlnlllgcfl
181 mgeshkgerr pmlrafnpv sswfwargmt ivaalmtvff imqlvgqypa alwifgedr
241 frwsatmigl slavfgilha laqafvtgpa tkrfgekqai iagmaadalq yyllafatrg
301 wmafpmill asggigmpal qamlsrqvdd dhqgqlqgsl aaltsltsit gplivtaiya
361 aaastwngla wivgaalylv cipalrrgaw sratst
```

Figure 3: Primary amino acid sequence of two *mdr* genes isolated first (1965) in pBR322 recombinant plasmid. Sadly, so many *amp* and *tet* genes isomers are now generated that these two sequences are very much abandoned but originator of 20 betalactamases and 20 tetracycline drug efflux isomers.




Figure 4: Structures of pEGY1-MCR-1 and pK109R MDR conjugative plasmids. It lost many *Tra* genes but acquired metal drug resistant genes, DNA methyl transferases, vitamin synthesizing genes and many transposons or IS elements. It also has *mcr-1* gene which discovered in 2016. In pK-109-R plasmid ESBL *blaOXA* and *blaCTX-M* proteins were indicated and had no similarity to Amp protein as in figure-3 but could lyse oxacillin and cefotaxime beta-lactams.

drugs intake killing gut bacteria and preventing vitamin biosynthesis were blamed for the creation of *mdr* genes but water chemical and metal toxicities were also a concern.

As for now, MDR plasmids are stable and have large space to acquire multiple similar genes needed for new gene creation increasing enzyme concentration. So many MDR plasmids had now multiple integrases (*int*), recombinases (*tnp*), DNA topoisomerases (*topoIII*), reverse transcriptases (*maturase*) and promoter-enhancers. Since 2010 WHO declared war against MDR bacteria with Action Plan worldwide. Lately, drug companies introduced β -lactamase inhibitor (cavulinate, sulbactam, avibactam) combination therapy but problems are continuing. In truth avibactam still a good drug against penicillinases but not others inhibitors. Most devastating fact, carbapenems are clustered in large conjugative plasmids in presence of ESBL enzymes like KPC-2, VIM, OXA-23, OXA-210 and diverged drug acetyl/phospho transferases including PBPs and also many drug efflux genes (10-15 *mdr* genes in one plasmid). Those bacteria are named as superbugs and such infections must be treated in the developed countries like UK and USA. A prototype pEGY1 plasmid structure was presented in Figure 4A which had *mcr-1* *mdr* gene (discovered in 2016) that could inactivate colistin drug which so far used in case of superbug infection. In fact drug industry once made new drug derivative to suppress the action of an *mdr* enzyme, a new beta-lactamase is generated like *blaNDM-1* discovered in 2009. The




Figure 5: History of generation of many *bla* (beta-lactamases) *mdr* genes that degrade higher derivatives of penicillins. *blaTEM* do not cleave cefotaxime but *blaCTX-M*, *blaOXA-23* and *blaNDM-1* do. Similarly, *blaOXA-1* do not cleave meropenem but *blaKPC-2* and *blaNDM-1* cleave all. So new gene creation to inactivate any new antibiotic is easy and ubiquitous now. Apart from beta-lactamases, phosphotransferases (*aph*), acetyltransferases (*aac*) and adenyltransferases (*aad*) are created in plasmids to inactivate aminoglycoside and fluoroquinolone antibiotics.



CP022052.2) has enterohemolysin (protein id. ASE51239; 988aa; RTX Toxin c-terminus) and toxin B (protein id ASE51195; 3169aa) but no *mdr* genes. Many toxin genes (*netB*, *cpe*, *cpe2*, *iota*) in plasmids of *Clostridium perfringens* reported and few are MDR conjugative [37]. The plasmid pCP8533etx (accession no. AB444205; 65kb) has epsilon-toxin and beta-toxin including ABC transporter, *thiF* vitamin synthesizing gene and DNA methylase but no *amp*, *tet* or *strAB* ancestral *mdr* genes were found. The plasmid pCPPB-1 (accession no. AB604032; 67kb) has ioto toxin-ia/ib and enterotoxin including histidine kinase and response regulator genes. The plasmid pCW3 (accession no. DQ366035; 46kb) has acquired *tetA* and *tetM* tetracycline resistant genes including DNA methyl transferases and *Arc* transcriptional regulator but no *mdr* gene. However, in large plasmid pCLK (266kb), we found neurotoxin cluster (protein ids. ACQ51342, ACQ51274, ACQ51172, ACQ51216) and also hemagglutinin (HA33) RICIN family lectin protein as well as penicillin resistant protein (protein id. ACQ51167; *pen1A*), AAC acetyl transferase, MATE type drug transporter, DNA methyltransferases, RNA polymerase, DNA polymerase III and *ThiH* vitamin metabolizing genes. Toxin genes in *Clostridium perfringens* plasmids (<100kb) were sequenced, As for example, pJIR3537 (*netB*), pCP8533etx (*etx*, *cpb2*), pCPF5603 (*cpe*, *cpb*) and pCPPB-1 (*cpe*, *iota*) toxin genes but no *mdr* gene was found (*bla*, *tet*, *cat*, *aac*, *aph* or *sul1*). But small R-plasmid pIP401 has *catmdr* gene and 4.7kb pCW3 plasmid has *tetM* gene for tetracycline binding protein where as no toxin gene has assembled yet.. Similarly, large plasmid pRSJ10_1 (266kb; accession no. CP013684) of *Clostridium botulinum* has penicillin resistant protein (*pen1A*), hemagglutinin toxin (protein id. APQ78847), C5 Methyl transferase and vitamin metabolizing genes like thiamine synthase and precorrin methylase. Similarly, in another *C. botulinum* plasmid pJIR4150 (89kb) has autolysin (protein id. CRG98306), glycosyl transferase toxin (protein id. CRG98303), bacitracin transporter and putative acetyl transferase (accession no. LN835296).

We searched toxin genes in large or small plasmids of *Vibrio cholerae*. As for example, single *mdr* gene plasmids are pVCR94deltaX (*sul2*); pKA1 (*dhfr*); AY958065 (*strA*) and multi-*mdr* genes plasmids are pNDM-116-17 (*arr3*, *cmlA*, *blaOXA-10*, *aadA1*, *mphE*, *msrE*, *sul1*, *blaNDM1*); pV1447 (*tetD*, *mel*, *mph2'*, *aadA*, *sul1*, *dhfr*, *blaTEM1*); and pCR94 (*tetC*, *tetB*, *catA1*, *aph3'-1b*, *aph6'-1d*, *blaCARB-4*, *dhfr*, *QAEdelta*, and *sul1*) were important but no toxin gene indicating *STX* gene was yet chromosomal (see, accession nos. LN831185, KM083064, NZ_CP033514) (De et al. 1951). We also checked the *Salmonella enterica* large conjugative plasmids pF8475, p109/9, pHCM1, pB71 and pR64 with 9, 7, 6, 4 and 2 primitive *mdr* genes (*blaTEM*, *strAB*, *dhfr*, *sul1/2*, *tetB/A*, *aadA*, *aph3'*, *aacC2* etc.) but no toxin genes (accession nos. KP899804, KP899805, AL513383, KP899806, AP005147 respectively). Study indicated that *sea*, *sec*, *sed*, *see*, *eta*, and *etb* enterotoxin genes were associated in *Staphylococcus aureus* pathogenesis. We detected such genes in many *S. aureus* plasmids. As for example, 27424bp pSM31 plasmid contained *ser*, *sej*, *sed* enterotoxin genes (protein ids. AKS10460/61/63) and *blaZ mdr* gene including *blaR1* and *blaI* regulatory genes. Similar plasmid pSA564-fus has enterotoxins (protein ids. ATL64011/12/14) and also in plasmid pSK67 (protein

ids. ADA80031/32/34). Similarly, 43396bp pV2200 plasmid contained only *sej* enterotoxin (protein id. ALK43110) but *mph2'* aminoglycoside phosphotransferase, ABC drug efflux protein and *blaZ/blaR1/blaI* locus involved in induced penicillin resistance. Our hypothesis is if toxin genes are symbiotically protected, then their presence in plasmid would be more random similar to *mdr* genes. However, the present notion to use gene therapeutics (antisense, ribozyme, siRNA) may alter the genetic signaling (recombination) with rapid acquisition of toxin genes from chromosome into *mdr* plasmids.

Detection of virulence genes in MDR plasmids during multi-resistant pathogenesis

Virulence genes like fimbriae biogenesis proteins (*FimA/B/H*), *HlyA/D*, *foeG*, *estII*, *iucD*, *fanA* and other regulatory proteins have been implicated in the pathogenesis of *Escherichia coli*, *Salmonella enterica* and *Mycobacterium tuberculosis*. However, such genes were associated with chromosome. But localization of toxin genes, transcription regulatory genes and vitamin synthesis genes in MDR plasmids suggested that *vir* genes might also be mobilized into MDR conjugative plasmids. In conjugative plasmids pAPEC-02-211A-colV, pAMSC2, and pQnrS1_035148, we found many siderophore genes like aerobactin A/C/D as well as few *mdr* genes like *QnrS1* or *dhfr* and few drug efflux genes like *tetA* (protein id. AWX36385) and *macB* MFS drug efflux gene (accession nos. CP030791, CP031107, CP029368). A FAD-binding protein and cobalamin biosynthesis protein (*cobW*) were also detected (protein ids. AXF92256, AXF92236). Importantly, *Tra* genes are deleted in many MDR conjugative plasmids to give place for IS-elements and transposons absolutely required for recombination and transposition to create new *mdr* gene (*blaNDM-16* or *mcr-4* or *blaOXA-555*) against toxic new drug derivatives (imipenem, colistin and levofloxacin etc.).

Mobilization of vitamin metabolizing genes into plasmids to help bio-film symbiosis

We further searched the vitamin metabolizing genes in plasmids to confirm our hypothesis that such genes will be transferred into *mdr* conjugative plasmids to increase synthesis of vitamins required for >30000 enzymatic reactions in human metabolosome to avert the action of repeated doses of complex antibiotics. In Table 1 we presents data of such GenBank search confirming that *thiA/H/I/E/E*, *cobQ/S*, *pdxH*, *bioT* etc genes could be easily detected in plasmids but such genes were very prominent in many *Rizobium* plasmids. Thus our study confirmed that gut biofilm bacteria still under crisis to continue vitamin synthesis to save intestinal cells.

Mobilization of many transcription factors into MDR conjugative plasmids

GenBank search indicated a overwhelming transposition of transcriptional regulators into MDR plasmids (Table 2). Multi-resistant *K. pneumoniae* plasmid pKP530 (accession no. KF793937; 61kb) has *Tet^R*, *Lys^R* and *Mph^R* transcriptional regulators at the adjacent of *tetA*, *sul1* and *mph2'-1A* *mdr* genes (Table 3). However, such regulators may also control the

Table 1: Toxin Genes in MDR plasmids associated with *mdr* genes.

Plasmid accession and name of Bacteria	Toxin name and Protein Id	Associated <i>mdr</i> genes	Other important genes
KU549175 <i>A. baumannii</i>	Zeta toxin (AMQ95289), Hemolysin D	aphA (AMQ95356), copA (AMQ95338), cusA (AMQ95343)	ThiAB, ThiED, ThiF,
CP015022 <i>E. coli</i>	Toxin B (AMW46268) Hemolysin D (AMW46315/7) RTX toxin (AMW46316)	rRNA Adenine di-Methylase (AMW46255)	Type II secretion proteins
KR091911 <i>S. enterica</i>	Rhs insect toxin	Sul1, aad, dhfr, NDM1, aac6', mph, mel, CMY16, strB/A, tetA, floR	vWFS (AKN19321); PAPS (AKN19247)
KX156773 <i>E. coli</i> K-12	Rhs insecticidal toxin (AOB42019)	blaTEM1 (AOB42023)	cobS (AOB41981); arsH, dcm-1
KM396300 <i>Salmonella enterica</i>	HipA toxin (AKB10543)	blaCTX-M-15 (AKB10498) aac (AKB10489)	
CP010891 <i>S. aureus</i>	Ser (ALD82310) Sej (ALD82311) Sed (ALD82312)	blaZ	blaR1, blaI
MG591702 <i>Escherichia coli</i>	HipA toxin (AVV81661)	blaCTX-M-14 (AVV81644) mphA2' (AVV81651) Mcr-1 (AVV81693)	TerF/C/A/Z/Y
CP000963/CP001081 <i>Clostridium botulinum</i>	Neurotoxins: BivA4 (ACQ51342), BvB (ACQ51274), toxinX2 (ACQ51172) and toxinX3 (ACQ51216); Hemagglutinin-RICIN family (ACQ51131)	Pen1A (ACQ51167), AAC (ACA57573), MATE (ACQ51423)	ThiH, Topo-I, Helicase, ABC (ACQ51212)
CP014498 <i>Escherichia coli</i>	Enterotoxin (WP_001446689)	ANT3"-Ia, sul1, mphA, aph3"-1b, aph6-1d", MFS, tetA, EmaA, dhfr, AAC3-IId", blaTEM-1	DAF3560 DAF3883
CP013684 <i>Clostridium botulinum</i>	Hemagglutinin (APQ78847)	Pen1A (APQ78573) C5 methyl transferase (APQ78745)	ThiF (APQ78762), Precorrin-methylase (APQ78545), DNA PolIII- α β γ
MF622050 <i>S. aureus</i>	Ser (ALT64011) Sea (ATL64012) Sed (ATL64014)	fusB (ATL64035) blaZ	blaR1, blaI
KM877269 <i>Salmonella enterica</i>	HipA (AKG90205)	aphA1, sul1, aadA1, aadA2, sul2, aac3'-IV, aac6'-1b-cr, blaOXA, cat, arr3,	terE/D/C/X/Y/Z trhH/B/I, oqxB/A, cmlA, floR

expression of *aac6'-1b-cr* (protein id. AHF45947), *blaOXA-30* (protein id. AHF45948), *blaDHA-1* (protein id. AHF45968) and *catB3* (protein id. AHF45949) *mdr* genes were located in same plasmid likely as poly-mRNA. *Salmonella enterica* plasmid pA3T (accession no. KX421096; 253kb) *fosA3* and *Oqx*B genes were regulated by adjacent *tet^R* and *oqx^R*, and other important *mdr* genes like *blaOXA-1* (protein id. AOR05995), *catB3* (protein id. AOR05996), *Arr3* (protein id. AOR05997) and *ANT3''* was also detected in same plasmid. Another *Salmonella Typhimurium* MDR strain GDS147 plasmid (accession no. KM877269) contained *tnpR* regulator at the downstream of *dhfr*, *aadA1/A2* and *cmlA* chloramphenicol efflux genes. *Lys^R* TF (protein id. AKG90162) was also located at the upstream of linked *floR*, *aac6'-1b-cr*, *sul1*, *aph*, *aac3'-IV* and *blaOXA-1* (protein id. AKG90176) *mdr* genes. In ESBL plasmid pKP13f (accession no. CP004000; 295kb) located *aad3''* streptomycin 3'' adenylyl transferase and *aacA4* aminoglycoside 6' acetyl transferase likely were regulated by transposon promoters; where as *dhfr*, *aadA2*, *cmlA1*, *blaCTXM-2*, *blaOXA-9*, *blaSHV-12* and *blaTEM-1* genes might be activated by *int* or *tnpA* promoters. A HTH deo^R-type transcriptional regulator (protein id. AHE47447; nt. 228311) was located in the middle of such *mdr* genes. We also propose the roles of *tet^R* (protein id. AFG21523) and *Lux^R* (protein id. AFG21575) TF in *Salmonella enterica* subsp. *enterica* serovar Heidelberg plasmid pSH696_135 MDR pathogenesis controlling *strAB*, *sul1*, *blaAmp-C*, *blaCMY-2*, *dhfr*, *floR* and *aad2''-IB* genes giving multi-resistance (see, accession no. JN983048; Table 3).

pNDM1-010045 plasmid (accession no. CP028560, 190kb) has *blaNDM-1* (protein id. AVZ84373), *sul2* (protein id. ANZ84383), *aac3'-I* (protein id. AVZ84355), *mph2'* macrolide phosphotransferase (protein id. AVZ84457), and *blaOXA-58* ESBL (protein id. AVZ84486). Such *mdr* genes were likely regulated by *ArsR* (protein id. AVZ84490), *AraC* (protein id. AVZ84463), *XRE* (protein id. AVZ84345) and *LysR* (protein id. AVZ84385) located in the same plasmid including *IS-3*, *IS-4* and *IS-30* elements. Similarly, *K. pneumoniae* plasmid pPMK1-NDM (accession no. CP008933; 304kb) has three *blaNDM1* genes at nt. 47947, 56535 and 65123 including *blaOXA1* and *blaCTX-M* beta-lactamase isomers giving complete resistance to penicillin, cephalosporins and carbapenems. *Mer^R* type transcriptional regulator may be important in this plasmid as well as other *mdr* genes like *aacA4*, *dhfr*, *aac6'-Ia*, and *ANT3''-Ia*. In *K. pneumoniae* 154kb plasmid pCR14_2 (accession no. NZ_CP015394) we detected *OXA-2* enzyme including *mdr* genes, *aac6'-1b*, *QacEA*, *sul1*, *CTX-M-2*, *TEM-1* and *aac3'-IIa*, clustered at nt. 111745-127396 region and many *Tra* genes (*TraI/K/B/V/W/U/N*) and surprisingly nt. 1-40000 region had many unknown genes (DUF domain proteins). Unusually no distinct transcriptional regulator was detected but an *ArsR*-like TF.

The plasmids discussed above have no great toxin gene to discuss but the plasmids which had toxins as in Table-3 might have many transcriptional regulators. As for

**Table 2:** Detection of Vitamin metabolizing genes in MDR conjugative plasmids of bacteria.

Vit genes	PLASMID	Bacteria (Genus)	Accession no	Protein id	Enzyme name and function
<i>thiA</i>	p22ES-469, 469kb	<i>Enterobacter</i>	CM008897	PIA01545, 213aa	Thiamine phosphate synthase
<i>thiH</i>	p22ES-469, 469kb	<i>Enterobacter</i>	CM008897	PIA01549, 375aa	2-imino acetate synthase
<i>thiI</i>	pSymA	<i>Sinorhizobium</i>	AE006469	AAK65851, 566aa	Thiamine-PP binding protein
<i>thiG</i>	P1, 125kb pRLN1, 110kb	<i>Rizobium</i> <i>Rizobium</i>	CP016287 CP025013	ANP89691, 257aa AUW45996, 257aa	Catalyses the formation of thiazole. EC: 1.5.3.8.
<i>thiS</i>	P1, 125kb	<i>Rizobium</i>	CP016287	ANP89692, 65aa	Ubiquitin-like sulphur carrier protein
<i>thiO</i>	P1, 125kb	<i>Rizobium</i>	CP016287	ANP89693, 329aa	FAD-dependent oxidoreductase
<i>thiC</i>	P1, 125kb pRLN1, 110kb p22ES-469, 469kb	<i>Rizobium</i> <i>Rizobium</i> <i>Enterobacter</i>	CP016287 CP025013 CM008897	ANP89694, 607aa AUW45993, 607aa PIA01544, 631aa	Phosphomethyl pyrimidine synthase
<i>thiF</i>	pKOX_R1, 354kb pC13-2, 104kb	<i>Klebsiella</i> <i>Acinetobacter</i>	CP003684 KU549175	AFN35065, 742aa AMQ95348, 576aa	Thiamine synthetase
<i>thiE</i>	P2, 181kb pRLN1, 110kb	<i>Vibrio</i> <i>Rizobium</i>	CP022555 CP025013	ASQ38758, 204aa AUW45997, 202aa	Thiamine phosphate pyrophosphorylase
<i>cobW</i>	P1, 125kb	<i>Rizobium</i>	CP016287	ANP89796	Cobalamine biosynthetic protein
<i>cobX</i>	pKHM-1, 166kb pVPS129, 157kb pRJ119-NDM1, 335kb pECAZ155_KPC, 272kb	<i>Citrobacter</i> <i>Vibrio</i> <i>Klebsiella</i> <i>Escherichia</i>	AP014939 KY014464 KX636095 CP019001	BAS21640, 425aa ARJ33497, 425aa APZ79705, 425aa AQV87400, 425aa	DUF3150 domain protein. Na ₂ Ca ₂ ex domain synthesizing genes
<i>cobQ</i>	pECAZ155_KPC, 272kb pVAS19, 187kb	<i>Escherichia</i> <i>Vibrio</i>	CP019001 KX957968	AQV87341, 261aa APU90883, 261aa	Cobalamine biosynthetic protein
<i>cobS</i>	pRJ119-NDM1, 335kb	<i>Klebsiella</i>	KX636095	APZ79701, 332aa	Cobalamine chelatase
<i>thfR</i>	pSymA, 135kb	<i>Sinorhizobium</i>	AE006469	AAK65825, 317aa	5,10 methylene tetrahydrofolate reductase, EC:1.5.1.20
<i>thfD</i>	pSymA, 135kb	<i>Sinorhizobium</i>	AE006469	AAK65824, 286aa	Formoyl tetrahydrofolate deformylase, EC:3.5.1.10
<i>pdxH</i>	P2, 181kb	<i>Vibrio</i>	CP022555	ASQ38911, 211aa	pyridoxamine 5'-phosphate oxidase
<i>bioC</i>	pCB782, 156kb	<i>Rizobium</i>	CP007068	AHG48429, 464aa	biotin carboxylase
<i>bioD</i>	pRLN1, 110kb	<i>Rizobium</i>	CP025013	AUW45720, 776aa	biotin sulfoxide reductase
<i>bioT</i>	pSHE-CTX-M, 193kb	<i>Shewanella</i>	CP022359	ASK71473, 412aa	acetyl-CoA carboxylase biotin carboxy carrier protein
<i>nicA</i>	pRLN1, 110kb	<i>Rizobium</i>	CP025013	AUW45731, 217aa	Nicotinamide amidase

example, *Enterobacter cloacae* large plasmid p22ES-469 nine transcriptional regulators like LexA, HTH, AcrR, UhpA, FadR, Zur, LysR, AraC, and SoxR (protein ids. PIA01506, PIA01710, PIA01737, PIA01760, PIA01793, PIA015031, PIA01796, PIA01716, and PIA01585 respectively) were accumulated. However, only GCN5 acetyl transferases and MFS drug efflux proteins were detected but no beta-lactamase gene. Sugar metabolising and vitamin synthesis genes were important aspect of this plasmid and likely were activated by numerous transcription factors (Table 3). So such analysis clearly indicated that toxin genes are rare in *mdr* plasmids but *mdr* genes are abundant with prominent transcriptional regulators.

Pseudomonas aeruginosa strain AR_0111 XDR clone MDR-island (accession no. CP032257) has many *mdr* genes (*bla*OXA-4, *ANT3*"-Ia, *cmlA*, *tetG*, *aac3*;-Ia, *sul1*, *vanA*, *mexEF*, *PBPs*) and many transcription factors like LysR (protein ids. AXZ90574, AXZ90543, AXZ95626, AXZ95001, AXZ95625, AXZ93389, AXZ93271, AXZ94943), HlyD (protein ids. AXZ95115), AraC (protein ids. AXZ95059, AXZ95038, AXZ95648, AXZ94991, AXZ94944, AXZ93336, AXZ95582), MexT (AXZ95056), GntR (AXZ93413), TenA (protein id. AXZ90500) and HTH (protein id. AXZ93247). Such results clearly demonstrated that chromosomal DNA as origin of transcriptional regulators and such genes mobilised into plasmids by recombination. If

MDR-islands have role in transferring the *vit* and *tf* genes into plasmids is not known. But once it is acquired by conjugative plasmid, then propagation will be occurred by conjugation. That way more and more *tf* and *vit* genes will be found in MDR conjugative plasmids in the future.

Gut biofilm and *mdr* genes are in symbiosis for vitamin synthesis and antibiotic void

We use 200,000 mt antibiotics per year. We are so depend on antibiotic use that survey has indicated common people like prescription drug even the disease is viral and auto-immunity will be developed within one week. Thus, every man use 10-20 prescription doses of antibiotics per year destroying gut microbiota disrupting the symbiosis between bacteria and intestinal cells. We believe that huge use of antibiotics are cause of multi-resistance today as well as metabolic diseases like diabetes, indigestion, tension and cancer. It is believed that lipopolysaccharides are in a signalling cascade to produce interleukins and cytokines by intestinal cells controlling biofilm (Figure 6).

Thus *mdr* gene creation is to protect human and animal from extinct although such discrepancies are balanced by prescription drugs like multi-vitamin capsule and probiotic capsule. As the higher derivatives are protective to some



Table 3: Transcriptional Repressors/Activators found in MDR-conjugative Plasmids.

Plasmid	Length	Accession	Genes	Protein Id	Position	Bacteria
pKP530	61kb	KF793937	<i>LysR</i>	AHF45969	41907-42791	<i>K. pneumoniae</i>
			<i>mphR</i>	AHF45975	47713-48297c	
			<i>tetR</i>	AHF45942	16409-17059	
pA3T	253kb	KX421096	<i>tetR</i>	AOR05955	91674-92024	<i>S. enterica</i>
			<i>lysR</i>	AOR05981	112158-112463	
			<i>arsR</i>		153970-154266c	
pHXY0908	249kb	KM877269	<i>tnpR</i>	AKG90156	100235-100795	<i>S. enterica</i>
			<i>lysR</i>	AKG90162	108216-10852	
			<i>hdtA</i>	AKG90272	211022-211390c	
pVPH1	183kb	KP688397	<i>acrR</i>	AJP18356	139368-139952c	<i>Vibrio sp.</i>
			<i>merR</i>	AJP18323	109685-110119c	
			<i>padR</i>	AJP18352	137579-137884	
pKP13e	81kb	CP003998	<i>korB</i>	AHE41911	35175-36113c	<i>K. pneumoniae</i>
			<i>flhC</i>	AHE41963	67546-68046c	
pI1-34TF	167kb	LN850163	<i>actR</i>	CRK62812	119708-120205c	<i>E. coli</i>
			<i>envR</i>	CRK62808	116345-117013	
pCFI-2	24kb	JN215524	<i>ampR</i>	AFL38287	21629-22504	<i>C. freundii</i>
			<i>pspF</i>	AFL38281	16338-17312c	
P12246J	11kb	KF680002	<i>korC</i>	AJR19475	7567-7863c	<i>K. pneumoniae</i>
pRH-R178	223kb	HG530658	<i>terW</i>	CDI45181	68740-69207	<i>E. coli</i>
			<i>rcnR</i>	CDI45274	129402-129674c	
			<i>pnbR</i>	CDI45304	156699-157106	
pKP13f	295kb	CP004000	<i>merR</i>	AHE47226	52706-53140	<i>K. pneumoniae</i>
			<i>korC</i>	AHE47411	202076-202342	
			<i>fmrR</i>	AHE47462	243670-243945	
			<i>deoR</i>	AHE47447	228311-229072	
pSH696_135	135kb	JN983048	<i>merD</i>	AFG21588	90691-91053	<i>S. enterica</i>
			<i>tetR</i>	AFG21523	30282-30950	
			<i>entR</i>	AFG21567	68855-69280	
			<i>flhC</i>	AFG21633	132922-133473	




Figure 6: Regulation of gut symbiosis between gut microbiota and intestinal cells for vitamin synthesis. Acquisition of many vitamin synthesis genes, growth regulatory genes and bio-molecule synthesis genes in MDR conjugative plasmids indicated that symbiosis might be tight and we could not use oral antibiotics to kill all gut microbiota.

blaKPC-2, *blaNDM-1*, *aph-III-1b*, *aac-6'-1b-cr* are *mdr* genes that could be effective in maintaining PAN multi-resistance. We detected the 0.002% bacteria have such genes over 45% bacteria have *blaTEM*, *tet*, *dhfr*, *sul*, and *cat* types early *mdr* genes. *blaNDM1* gene was detected in 2009 and *mcr-1* gene was detected in 2016 making imipenem and colistin drugs useless. Scientists detected >500 mutant isomers for each *blaTEM*, *blaOXA*, *blaCTX-M* and *blaAmp-C*, where as *blaOXA* has at least 12 distinct sequence types with only 20-40% similarities at specific zones. It appeared that multiple antibiotics use have greatly facilitated the recombination among the various plasmids in MDR bacteria and it was just few days to months to make a new genotype with increase in drug MIC. Such discussion confirmed that (i) we will continue to use antibiotics, (ii) *mdr* genes will recombine to make more deadly *mdr* gene isomer (iii) we will face more health hazards, (iv) multi-vitamin and bifidobacteria capsule or curd will improve the antibiotic action (v) more diabetes, mental disorders and cancer will follow if we disturb bio-film and (vi) greedy politicians and rich men will bring World War III to save themselves from distressed people.

extent, amoxicillin + clavulanic acid or cefotaxime, azithromycin and ofloxacin are very much used in India. However, meropenem, amikacin, linezolid are best drugs although *blaOXA-58*,

Injection of *mdr* bacteria onto rats have no immediate ill effects

When we tested the MDR-cure extract on rats, we found that 93% MDR bacteria *Escherichia coli* KT-1_mdr were eliminated by phyto-extract but rats appeared healthy for long time. So we continued the study. We intradermally injected *E. coli* KT-1_mdr and *P. aeruginosa* PB-2_mdr five different positions but no death of the animals up to three months and rats were shown very active with weight gain (Figure 7). The MDR bacteria were characterized in Figure 8 demonstrating plasmid profiles, *bla*TEM and *bla*CTX-M *mdr* genes PCR detection in isolated plasmids and inhibition of those MDR bacteria by different phyto-extracts. Growth rate was good and after one month bacterial load could be detected in blood but three experiments showed no death of animals between 3-4 months. Such bacteria were confirmed for *bla*TEM, *bla*CTX-M, *tetA*, *acrAB*, and *aac6'-1b* genes (24,30). Thus, we concluded that *mdr* genes were not so injurious to health but only did create the antibiotic void. However, those bacteria were imipenem sensitive. This data was supported US Microbiome Project where many *mdr* genes were sequenced from bacteria isolated from normal individual [44-45].



Figure 7: Good health activity of rats after injection of MDR bacteria *Escherichia coli* KT-1_mdr and *Pseudomonas aeruginosa* DB-2_mdr. Repeated oral and subcutaneous injections of MDR bacteria ($0.5 \text{ ml log phase bacteria } 2.5 \times 10^6 \text{ cfu/ml}$) produced bacteremia but animals are in good health upto >3 months follow up.




Figure 8: Characterization of MDR bacteria and their inhibition by MDR-Cure Phyto-Extracts. (A) Agarose gel stained with EtBr under UV illumination of Plasmid profiles of few MDR bacteria isolated from Ganga River water, and cow milk; (B) PCR detection of *bla*CTX-M beta-lactamase gene; (C) DNA sequencing of *bla*TEM-1 gene and (D) inhibition of MDR bacteria by *Cassia fistula*, *Trapa bispinosa* and *Shorea robusta* phyto-chemicals and meropenem $10 \mu\text{l}$ (5 mg/ml) was used as standard. TU1 and TU2 are TLC purified two fractions from *Trapa bispinosa* fruit peel.

Conclusion

Life creation is due to chemical evolution with assembly of many bio-molecules (amino acids, lipids, nucleotides, carbohydrates and vitamins). Darwin's adaptation theory tells the unique way of changes in cellular structure and metabolism in different eco-system. About 40% of people reside at the bank of Ganga River and many big industries are made nearby releasing many pollutants and excretory matters which support lower life forms but also toxicity present. In Ganga River, we see number of bacteria is increasing with 45% resistant to semi-synthetic drugs ampicillin and amoxicillin and 26% resistant to tetracycline. Such drugs had cured most infections between 1940-1990 although gradual increase in drug-resistance pathogens were detected in many continents as early as 1960. Thus, superbugs were highly contaminated in water resources of Ganga River, Bay of Bengal and likely rest of the world. G20 leaders formulated the action plan against MDR bacteria spread. WHO warned that if alternative to antibiotics would not be discovered, very fatal human loss might be occurring in the future? High antibiotic concentration in global water is a concern due to huge population increase with antibiotic consumption and use of antibiotics in agricultural land and livestock production. Although toxin genes are main regulators of pathogenesis but $1/4$ unknown genes surely have some roles in bio-film formation and gut microbiota protection and thus maintaining MDR pathogenesis. Further, high rate antibiotic uses in expression vectors containing inducible operon (*tetO*, *blaO*) for enzymes and anti-metabolites production have also been questioned [13].

We presented the data that other than *mdr* genes, many important genes were assembled in MDR Conjugative Plasmids increasing the calamity of multi-resistance. As for example, toxin genes (Table 1), vitamin genes (Table 2), transcriptional regulatory genes (Table 3) were detected in plasmids. The modern plasmid proto-type structure was presented in Figure 4 and mechanism of new β -lactam drugs vs beta-lactamase isomers generation with time was presented in Figure 3. Thus, study of *mdr* genes to control multi-resistance may not be possible and other plasmid associated genes must be addressed. So our effort to describe the plasmid associated toxin and regulatory genes is important to know the regulatory issues of plasmid-mediated pathogenesis due to augmented expression of toxins and virulence genes. Likely herbal antibiotics research has given priority in India as there are enough medicinal plants and spices available as described in Sanskrit books Charaka Samhita, Susruta Samhita and Atharva Veda [4,6]. New technologies like gene medicines (ribozymes, miRNA, antisense RNA, and metal nanotechnology) have been welcome to stop the horror of MDR bacterial pathogenesis. We believe in herbal heterogeneous antibiotics and we demand conservation of medicinal plants worldwide. Our slogan "save plants and use as medicine" to save millions of people those are dragged into a nasty poverty line each year due to high cost of antibiotics. Of course, drug void will increase with time as 20-60 transposable elements and rDNA recombinases were assembled in plasmids making easy new *mdr* gene creation [20,47,48]. In summary, we proved that *mdr* genes are not



immediate threat. We believe that *mdr* genes will be rescued if we stop huge complex antibiotic intake. That way injectables may be better than oral antibiotics. Anyway assembly of too many *mdr* genes in plasmids and chromosome islands forced scientists to discover new targets and new methods for the control of bacterial pathogenesis like phage therapy, gene therapy and nanodrug carriers. But immediate high cost of drugs dragged millions of peoples to poverty line as no insurance coverage in the poor African and Asian countries. Thus, drug resistance is a brand name discussed everywhere as in cancer therapy and viral infection and likely a dark age of antibiotics has appeared and thus easy use of antibiotics and anti-cancer drugs may not be a solution today complicating medical field. Surely, drug efflux proteins (AcrAB/CD, MexAB/CD/EF, MacAB, MtrCD) in plasmids are causing more threat to medicine use in clinical therapies.

Acknowledgement

We thank Late Dr Jagat Bandhu Medda of Oriental Association of Education and Research for funding. AKC is Associate Professor of Biochemistry at OIST. Shampa Bhatta is Ex-student of Biotechnology, Sankalita Datta is MSC 4th Sem Biochemistry student and SD, MD, CH are MSC 4th Sem Biotechnology students, Vidyasagar University. Kousik Poria is IIT GATE qualified PhD student.

Conflict of interest and Ethical Issues

None has involved in any conflict of interest and other ethical issues.

References

- Blower TR, Short FL, Rao F, Mizuguchi K, Pei XY, et al. (2012) Identification and classification of bacterial Type III toxin-antitoxin systems encoded in chromosomal and plasmid genomes. *Nucleic Acids Res* 40: 6158-6173. [Link: https://bit.ly/2JFhHSR](https://bit.ly/2JFhHSR)
- Fozo EM, Makarova KS, Shabalina SA, Yutin N, Koonin EV, et al. (2011) Abundance of type toxin-antitoxin systems in bacteria: searches for new candidates and discovery of novel families. *Nucleic Acids Res* 38: 3743-3759. [Link: https://bit.ly/2UFnq14](https://bit.ly/2UFnq14)
- Okeke IN, Laxmaninarayan R, Bhutta ZA, Duse AG, Jenkins P, et al. (2005) Antimicrobial resistance in developing countries. Part 1: recent trends and current status. *Lancet Infect Dis* 5: 481-493. [Link: https://bit.ly/2xML5DU](https://bit.ly/2xML5DU)
- Chakraborty AK (2016) Multi-drug resistant genes in bacteria and 21st Century problems associated with antibiotic therapy. *Biotechnol Ind J* 12: 113-114. [Link: https://bit.ly/2xKDXIc](https://bit.ly/2xKDXIc)
- McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, et al. (2013) The Comprehensive Antibiotic Resistance Database. *Antimicrob Agents Chemother* 57: 3348-3357. [Link: https://bit.ly/2UFnBtg](https://bit.ly/2UFnBtg)
- Laxminarayana R (2014) Antibiotic effectiveness: Balancing conservation against innovation. *Science* 345: 1299-1301. [Link: https://bit.ly/2UEgEsG](https://bit.ly/2UEgEsG)
- Xu ZQ, Flavin MT, Flavin J (2014) Combating multi-drug resistant gram-negative bacterial infection. *Exp. Opin. Invest. Drugs* 23: 163-182. [Link: https://bit.ly/3aCwHg5](https://bit.ly/3aCwHg5)
- Davis J, Davies D (2010) Origins and Evolution of Antibiotic Resistance. *Microbiol Mol Biol Rev* 74: 417-433. [Link: https://bit.ly/2V31dcf](https://bit.ly/2V31dcf)
- Chakraborty AK (2015) High mode contamination of multi-drug resistant bacteria in Kolkata: mechanism of gene activation and remedy by heterogenous phyto-antibiotics. *Indian J Biotechnol* 14:149-159. [Link: https://bit.ly/3aKMVUC](https://bit.ly/3aKMVUC)
- Tortora GJ, Funke BR, and Case CL (2016) *Microbiology: An Introduction*. 12th edi. ISBN: 9780321929150. [Link: https://amzn.to/2xPUP9X](https://amzn.to/2xPUP9X)
- Sigeris HE (1987) *A History of Medicine: Early Greek, Hindu and Persian Medicine*, vol. II, New York, Oxford University Press. ISBN: 9780195050790. [Link: https://amzn.to/2UYN7J7](https://amzn.to/2UYN7J7)
- Chakraborty AK (2017) Ganga action plan, heterogeneous phyto-antibiotics and phage therapy are the best hope for India tackling superbug spread and control. *Indian J Biological Sciences* 23: 34-51. [Link: https://bit.ly/2UGvRt9](https://bit.ly/2UGvRt9)
- Chakraborty AK, Poiria K, Saha D, Halder C, Das S (2018) Multidrug-Resistant Bacteria with activated and diversified MDR Genes in Kolkata Water: Ganga Action Plan and Heterogeneous Phyto-Antibiotics tackling superbug spread in India. *American J Drug Delivery Therapeutics* 5: 1-9. [Link: https://bit.ly/2ypECPx](https://bit.ly/2ypECPx)
- Flaming A (1928) On the antibacterial action of cultures of a *Penicillium* with special reference to their use in the isolation of *B. influenzae*. *British J Exp Pathol* 10: 226-236. [Link: https://bit.ly/3bS9ab0](https://bit.ly/3bS9ab0)
- Waksman SA, Woodruff HB (1940) The soil as a source of microorganisms antagonistic to disease-producing bacteria. *J Bacteriol* 40: 581-600. [Link: https://bit.ly/3aFnB2g](https://bit.ly/3aFnB2g)
- Schatz A, Bugle E, Waksman SA (1944) Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. *Exp Biol Med* 55: 66-69. [Link: https://bit.ly/3c198xZ](https://bit.ly/3c198xZ)
- Abraham EP, Chain E (1988) An enzyme from bacteria able to destroy penicillin. *Rev Infectious Diseases* 1940. 10: 677-678. [Link: https://bit.ly/2wSgogJ](https://bit.ly/2wSgogJ)
- Boliver F, Rodriguer RL, Greene PJ (1977) Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. *Gene* 2: 95-113. [Link: https://bit.ly/3aGjz3](https://bit.ly/3aGjz3)
- Chakraborty AK (2016) Multi-drug resistant genes in bacteria and 21st Century problems associated with antibiotic therapy. *Biotechnology: An Indian Journal*. 12: 114 [Link: https://bit.ly/2xKDXIc](https://bit.ly/2xKDXIc)
- Chakraborty AK (2019) Heterogeneous phyto-antibiotics and other future therapeutics against multi-drug resistant bacteria. *Advances Biochemistry* 7: 34-50. [Link: https://bit.ly/3dV1WF6](https://bit.ly/3dV1WF6)
- Chakraborty AK (2016) Complexity, heterogeneity, 3-D structures and transcriptional activation of multi-drug resistant clinically relevant bacterial beta-lactamases. *Trends Biotechnol-open access* 2: 1-001.
- Chakraborty AK (2019) Current status and unusual mechanism of multi-resistance in *Mycobacterium tuberculosis*. *J Health Med Informatics* 10: 328. [Link: https://bit.ly/2UZaHWa](https://bit.ly/2UZaHWa)
- Kumarasamy K, Kalyanasundaram A (2012) Emergence of *Klebsiella pneumoniae* isolate co-producing NDM-1 with KPC-2 from India. *J Antimicrob Chemother* 67: 243-244. [Link: https://bit.ly/2UGXfas](https://bit.ly/2UGXfas)
- Chakraborty AK, Pradhan S, Das S, Maity M, Sahoo S, et al. (2019) Complexity of OXA Beta-Lactamases involved in Multi-Resistance. *British J Bio-Medical Res* 3: 772-798.
- Sun J, Deng Z, Yan A (2014) Bacterial multidrug efflux pumps: Mechanisms, physiology and pharmacological exploitation. *Biochem Biophys Res Commun* 453: 254-267. [Link: https://bit.ly/2ysRcNX](https://bit.ly/2ysRcNX)
- Pansegrau W, Balzer D, Kruff V, Lurz R, Lanka E (1990) *In vitro* assembly of relaxosomes at the transfer origin of plasmid RP4. *Proc Natl Acad Sci. USA* 87: 6555-6559. [Link: https://bit.ly/3alvkfU](https://bit.ly/3alvkfU)
- Paterson ES, More MI, Pillay G, Cellini C, Woodgate R, et al. (1999) Genetic



- analysis of themobilization and leading regions of the IncN plasmids pKM101 and pCU1. *J Bacteriol* 181: 2572-2583. [Link: https://bit.ly/2xLHp5u](https://bit.ly/2xLHp5u)
28. Frost LS, Ippen-Ihler K, Skurray RA (1994) An analysis of the sequence and gene products of the transfer region of the F sex factor. *Microbiol Rev* 58: 162-210. [Link: https://bit.ly/2yyi0kZ](https://bit.ly/2yyi0kZ)
29. Botts RT, Apffel BA, Walters CJ, Davidson KE, Echols RS (2017) Characterization of Four Multidrug Resistance Plasmids Captured from the Sediments of an Urban Coastal Wetland. *Front Microbiol* 8: 1922. [Link: https://bit.ly/2V6zxDI](https://bit.ly/2V6zxDI)
30. Chakraborty AK (2017) Multidrug resistant bacteria from Kolkata Ganga River with heterogeneous MDR genes have four hallmarks of cancer cells but could be controlled by organic phyto-extracts. *Biochem Biotechnol Res* 5: 11-23. [Link: https://bit.ly/347lVw1](https://bit.ly/347lVw1)
31. Guo Q, Spychala CN, McElheny CL, Doi Y (2016) Comparative analysis of an IncR plasmid carrying armA, blaDHA1 and qnrB4 from *Klebsiella pneumoniae* ST37 isolates. *J Antimicrob Chemother* 71: 882-886. [Link: https://bit.ly/2V4nDu1](https://bit.ly/2V4nDu1)
32. Ganguly NK, Kaur T (1996) Mechanism of action of cholera toxin & other toxins. *Indian J Med Res* 104: 28-37. [Link: https://bit.ly/2UH9001](https://bit.ly/2UH9001)
33. Spangler BD (1992) Structure and function of cholera toxin and the related *Escherichia coli* heat-labile enterotoxin. *Microbiol Rev* 56: 622-647. [Link: https://bit.ly/2xQVvkqE](https://bit.ly/2xQVvkqE)
34. Galán JE (2016) Typhoid toxin provides a window into typhoid fever and the biology of *Salmonella Typhi*. *Proc Natl Acad Sci USA* 113: 6338-6344. [Link: https://bit.ly/3dXb8ZU](https://bit.ly/3dXb8ZU)
35. Dougan G, Baker S (2014) *Salmonella enterica* serovar Typhi and the pathogenesis of typhoid fever. *Annu Rev Microbiol* 68: 317-336. [Link: https://bit.ly/2xQVvkqE](https://bit.ly/2xQVvkqE)
36. Song J, Gao X, Galán JE (2013) Structure and function of the *Salmonella Typhi* chimaeric A(2)B(5) typhoid toxin. *Nature* 499: 350-354. [Link: https://bit.ly/2whzD2U](https://bit.ly/2whzD2U)
37. Gerdes K, Christensen SK, Lobner-Olesen A (2005) Prokaryotic toxin-antitoxin stress response loci. *Nat Rev Microbiol* 3: 371-382. [Link: https://bit.ly/39AosM](https://bit.ly/39AosM)
38. Park SJ, Son WS, Lee BJ (2013) Structural overview of toxin-antitoxin systems in infectious bacteria: a target for developing antimicrobial agents. *Biochim Biophys Acta* 1834: 1155-1167. [Link: https://bit.ly/2yyVXWt](https://bit.ly/2yyVXWt)
39. Wang X, Wood TK (2011) Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response. *Appl Environ Microbiol* 77: 5577-5583. [Link: https://bit.ly/34dJLem](https://bit.ly/34dJLem)
40. Wozniak RA, Waldor MK (2009) A toxin-antitoxin system promotes the maintenance of an integrative conjugative element. *PLoS Genet* 5: e1000439. [Link: https://bit.ly/2JCbJlx](https://bit.ly/2JCbJlx)
41. Ausubel FM, Brent R (1989) *In Current Protocols in Molecular Biology*. Greene publishing associates and Wiley-Interscience, New York.
42. Maniatis T, Fritsch EF, Sambrook, J (1982) *Molecular Cloning-A Laboratory Manual*. Cold Spring Harbour Laboratory, 1982. ISBN: 978-0879691363. [Link: https://amzn.to/2X6Ruo4](https://amzn.to/2X6Ruo4)
43. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain terminating inhibitors. *Proc Natl Acad Sci USA* 74: 5463-5467. [Link: https://bit.ly/2JzFQdz](https://bit.ly/2JzFQdz)
44. Le Chatelier E (2013) Richness of human gut microbiome correlates with metabolic markers. *Nature* 500: 541-546. [Link: https://go.nature.com/2X4tIZX](https://go.nature.com/2X4tIZX)
45. Jandhyala SM (2010) Role of the normal gut microbiota. *World J Gastroenterol* 21: 8787-8803. [Link: https://bit.ly/2V05jIB](https://bit.ly/2V05jIB)
46. Chakraborty AK (2018) Nucleic-Acids Based Nanocarriers, in "Nanocarriers for Drug Delivery". eds. Mahapatra et al. chapter-5; pp.155-172, Elsevier Press, Amsterdam. ISBN:978012814.640.
47. Chakraborty AK (2020) Chemical toxicities of both Intestine and environmental water caused genetic recombination in bacteria with the creation of MDR genes and drug void. *EC Pharmacology and Toxicology* 8: 1-14.
48. Chakraborty AK (2018) Poor correlation of diversified MDR genes in *Gonococci* plasmids: Does alteration in chromosomal DEGs, PBP2 and target Mutations sufficient to wide spread multi-resistance in *Neisseria gonorrhoeae*? *J Health Med Informat* 9: 1-8. [Link: https://bit.ly/39Aof68](https://bit.ly/39Aof68)

Discover a bigger Impact and Visibility of your article publication with Peertechz Publications

Highlights

- ❖ Signatory publisher of ORCID
- ❖ Signatory Publisher of DORA (San Francisco Declaration on Research Assessment)
- ❖ Articles archived in worlds' renowned service providers such as Portico, CNKI, AGRIS, TDNet, Base (Bielefeld University Library), CrossRef, Scilit, J-Gate etc.
- ❖ Journals indexed in ICMJE, SHERPA/ROMEO, Google Scholar etc.
- ❖ OAI-PMH (Open Archives Initiative Protocol for Metadata Harvesting)
- ❖ Dedicated Editorial Board for every journal
- ❖ Accurate and rapid peer-review process
- ❖ Increased citations of published articles through promotions
- ❖ Reduced timeline for article publication

Submit your articles and experience a new surge in publication services (<https://www.peertechz.com/submission>).

Peertechz journals wishes everlasting success in your every endeavours.

Copyright: © 2020 Poria K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Poria K, Bhatta S, Das S, Dey M, Chakraborty AK, et al. (2020) Mechanism of multi-resistant bacterial pathogenesis: MDR genes are not so deadly unless plasmid-mediated toxin, virulence and regulatory genes are activated. *Open J Bac* 4(1): 008-019. DOI: <https://dx.doi.org/10.17352/ojb.000013>